

**CALCIPOTRIENE- calcipotriene cream  
Glenmark Pharmaceuticals Inc.,USA**

-----  
**CALCIPOTRIENE CREAM USP, 0.005%**

**Rx only**

**FOR TOPICAL DERMATOLOGIC USE ONLY.**

**Not for Ophthalmic, Oral or Intravaginal Use.**

**DESCRIPTION**

Calcipotriene Cream USP, 0.005% contains calcipotriene, USP, a synthetic vitamin D<sub>3</sub> derivative, for topical dermatological use.

Chemically, calcipotriene, USP is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1 $\alpha$ ,3 $\beta$ ,24-triol, with the empirical formula C<sub>27</sub>H<sub>40</sub>O<sub>3</sub>, a molecular weight of 412.62 and the following structural formula:

Calcipotriene, USP is a white or almost white crystalline powder. Calcipotriene Cream USP, 0.005% contains 50 mcg/g anhydrous calcipotriene, USP in a cream base of benzyl alcohol, ceteth-20, cetostearyl alcohol, disodium hydrogen phosphate dihydrate, glycerin, medium chain triglycerides, mineral oil, monosodium phosphate monohydrate, purified water and white petrolatum.

## **CLINICAL PHARMACOLOGY**

In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D<sub>3</sub> (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D<sub>3</sub>.

Clinical studies with radiolabelled calcipotriene ointment indicate that approximately 6% ( $\pm$  3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques, or 5% ( $\pm$  2.6%, SD) when applied to normal skin, and much of the absorbed active is converted to inactive metabolites within 24 hours of application. Systemic absorption of the cream has not been studied.

Vitamin D and its metabolites are transported in the blood, bound to specific plasma proteins. The active form of the vitamin, 1,25-dihydroxy vitamin D<sub>3</sub> (calcitriol), is known to be recycled via the liver and excreted in the bile. Calcipotriene metabolism following systemic uptake is rapid, and occurs via a similar pathway to the natural hormone.

## **CLINICAL STUDIES**

Adequate and well-controlled trials of patients treated with calcipotriene cream have demonstrated improvement usually beginning after 2 weeks of therapy. This improvement continued with approximately 50% of patients showing at least marked improvement in the signs and symptoms of psoriasis after 8 weeks of therapy, but only approximately 4% showed complete clearing.

## **INDICATIONS AND USAGE**

Calcipotriene cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

## **CONTRAINDICATIONS**

Calcipotriene cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene cream should not be used on the face.

## **WARNINGS**

Contact dermatitis, including allergic contact dermatitis, has been observed with the use of calcipotriene cream.

## **PRECAUTIONS**

### **General**

Use of calcipotriene cream may cause transient irritation of both lesions and

surrounding uninvolved skin. If irritation develops, calcipotriene cream should be discontinued.

For external use only. Keep out of the reach of children. Always wash hands thoroughly after use.

Reversible elevation of serum calcium has occurred with use of topical calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.

### **Information for Patients**

Patients using calcipotriene cream should receive the following information and instructions:

1. This medication is to be used only as directed by the physician. It is for external use only. Avoid contact with the face or eyes. As with any topical medication, patients should wash their hands after application.
2. This medication should not be used for any disorder other than that for which it was prescribed.
3. Patients should report to their physician any signs of adverse reactions.
4. Patients that apply calcipotriene cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.).

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30 mcg/kg/day (corresponding to 9, 30 and 90 mcg/m<sup>2</sup>/day), no significant changes in tumor incidence were observed when compared to control. In a study in which albino hairless mice were exposed to both UVR and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors. Patients that apply calcipotriene cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of phototherapy in patients that use calcipotriene cream.

Calcipotriene did not elicit any mutagenic effects in an Ames mutagenicity assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, or in a micronucleus assay conducted in mice.

Studies in rats at doses up to 54 mcg/kg/day (324 mcg/m<sup>2</sup>/day) of calcipotriene indicated no impairment of fertility or general reproductive performance.

### **Pregnancy**

#### *Teratogenic Effects*

Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40 to 60% of the administered dose. Increased rabbit maternal and fetal toxicity was noted at 12 mcg/kg/day (132 mcg/m<sup>2</sup>/day). Rabbits administered 36 mcg/kg/day (396 mcg/m<sup>2</sup>/day) resulted in fetuses with a significant increase in the incidences of pubic bones, forelimb phalanges, and incomplete bone ossification. In a rat

incidence of pain, swelling, redness, pruritus, and incomplete bone ossification. In a rat study, oral doses of 54 mcg/kg/day (318 mcg/m<sup>2</sup>/day) resulted in a significantly higher incidence of skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The maternal and fetal calculated no-effect exposures in the rat (43.2 mcg/m<sup>2</sup>/day) and rabbit (17.6 mcg/m<sup>2</sup>/day) studies are approximately equal to the expected human systemic exposure level (18.5 mcg/m<sup>2</sup>/day) from dermal application. There are no adequate and well-controlled studies in pregnant women. Therefore, calcipotriene cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### **Nursing Mothers**

There is evidence that maternal 1,25-dihydroxy vitamin D<sub>3</sub> (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk. The systemic disposition of calcipotriene is expected to be similar to that of the naturally occurring vitamin. Because many drugs are excreted in human milk, caution should be exercised when calcipotriene cream is administered to a nursing woman.

### **Pediatric Use**

Safety and effectiveness of calcipotriene cream in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.

### **Geriatric Use**

Of the total number of patients in clinical studies of calcipotriene cream, approximately 15% were 65 or older, while approximately 3% were 75 and over. There were no significant differences in adverse events for subjects over 65 years compared to those under 65 years of age. However, the greater sensitivity of older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

### **Clinical Trials Experience**

In controlled clinical trials, the most frequent adverse experiences reported for calcipotriene cream, 0.005% were cases of skin irritation, which occurred in approximately 10 to 15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients.

### **Postmarketing Experience**

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions associated with the use of calcipotriene cream have been identified post-approval: contact dermatitis, including allergic contact dermatitis.

**To report SUSPECTED ADVERSE REACTIONS, contact Glenmark Pharmaceuticals Inc., USA at 1 (888) 721-7115 or FDA at 1-800-FDA-1088 or**

[www.fda.gov/medwatch](http://www.fda.gov/medwatch).

## **OVERDOSAGE**

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of topical calcipotriene. If elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored (see **PRECAUTIONS**).

## **DOSAGE AND ADMINISTRATION**

Apply a thin layer of calcipotriene cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of calcipotriene cream have been demonstrated in patients treated for eight weeks.

## **HOW SUPPLIED**

Calcipotriene cream USP, 0.005% is available in:

60 gram tube (1 tube per carton), NDC 68462-501-65

120 gram tube (1 tube per carton), NDC 68462-501-66

## **STORAGE**

Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not freeze.

Manufactured by:

### **Glenmark Pharmaceuticals Limited**

Colvale-Bardez, Goa 403513, India

Manufactured for:



### **Glenmark Pharmaceuticals Inc., USA**

Mahwah, NJ 07430

Questions? 1 (888) 721-7115  
[www.glenmarkpharma-us.com](http://www.glenmarkpharma-us.com)

February 2023

## **PACKAGE/LABEL PRINCIPAL DISPLAY PANEL-60 gm Carton**

NDC 68462-501-65



Manufactured for:  
 Glenmark Pharmaceuticals Inc., USA  
 Mahwah, NJ 07430  
 Product of Taiwan  
 GO/DRUGS/648  
 04/23  
 PE630920423-1



Questions? 1 (888) 721-7115  
 www.glenmarkpharma-us.com

NDC 68462-501-66

**Calcipotriene Cream USP, 0.005%**

FOR TOPICAL DERMATOLOGIC USE ONLY.  
 Not for Ophthalmic, Oral or Intravaginal Use.



Rx only

Net wt. 120 g

Each gram contains 0.05 mg of calcipotriene, USP in a cream base of benzyl alcohol, ceteth-20, cetostearyl alcohol, disodium hydrogen phosphate dihydrate, glycerin, medium chain triglycerides, mineral oil, monosodium phosphate monohydrate, purified water and white petrolatum.

**Usual Dosage:** Apply twice daily or as directed by physician. See insert for complete information.

**Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not freeze.**

**WARNING: Keep out of reach of children.**

NDC 68462-501-66

**Calcipotriene Cream USP, 0.005%**

FOR TOPICAL DERMATOLOGIC USE ONLY.  
 Not for Ophthalmic, Oral or Intravaginal Use.



Rx only

Net wt. 120 g

Calcipotriene Cream  
 USP, 0.005% / Net Wt. 120 g

Unvarnished area  
 23 mm x 49 mm for  
 Expiry Date and Lot No.

# CALCIPOTRIENE

calcipotriene cream

## Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:68462-501
<b>Route of Administration</b>	TOPICAL		

## Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
CALCIPOTRIENE (UNII: 143NQ3779B) (CALCIPOTRIENE - UNII:143NQ3779B)	CALCIPOTRIENE	50 ug in 1 g

## Inactive Ingredients

Ingredient Name	Strength
BENZYL ALCOHOL (UNII: LKG8494WBH)	
CETOSTEARYL ALCOHOL (UNII: 2DMT128M1S)	
CETETH-20 (UNII: I835H2IHHX)	
SODIUM PHOSPHATE, DIBASIC, DIHYDRATE (UNII: 94255I6E2T)	
GLYCERIN (UNII: PDC6A3C0OX)	
MEDIUM-CHAIN TRIGLYCERIDES (UNII: C9H2L21V7U)	

<b>MINERAL OIL</b> (UNII: T5L8T28FGP)	
<b>SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE</b> (UNII: 593YOG76RN)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>PETROLATUM</b> (UNII: 4T6H12BN9U)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68462-501-65	1 in 1 CARTON	06/10/2015	
1		60 g in 1 TUBE; Type 0: Not a Combination Product		
2	NDC:68462-501-66	1 in 1 CARTON	06/10/2015	
2		120 g in 1 TUBE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
ANDA	ANDA205772	06/10/2015	

**Labeler** - Glenmark Pharmaceuticals Inc.,USA (130597813)

### Establishment

Name	Address	ID/FEI	Business Operations
Glenmark Pharmaceuticals Limited		677318665	ANALYSIS(68462-501) , MANUFACTURE(68462-501)

Revised: 4/2023

Glenmark Pharmaceuticals Inc.,USA